Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population GlobeNewswire - Sat Jul 18, 2:15PM CDT

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated...

FDMT : 10.07 (-2.99%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Jul 17, 3:05PM CDT

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists GlobeNewswire - Tue Jun 30, 3:05PM CDT

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital GlobeNewswire - Mon Jun 29, 7:00AM CDT

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
HTGC : 15.73 (+0.58%)
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD GlobeNewswire - Mon Jun 29, 7:00AM CDT

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...

FDMT : 10.07 (-2.99%)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker GlobeNewswire - Fri Jun 26, 6:30AM CDT

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

FDMT : 10.07 (-2.99%)
VANI : 1.2800 (-7.91%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Jun 12, 3:05PM CDT

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT to Participate in Upcoming Investor Conferences GlobeNewswire - Wed May 27, 7:00AM CDT

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 10.07 (-2.99%)
MarketBeat.com
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy MarketBeat - Sat May 16, 7:02PM CDT

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development...

FDMT : 10.07 (-2.99%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri May 15, 3:05PM CDT

EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 10.07 (-2.99%)

Barchart Exclusives

No Matter Who Wins the Smartphone and AI Chip Races, ARM Stock Still Benefits Barchart - Sat Jul 25, 2:30PM CDT
Arm now leads x86 in AI servers and collects royalties from every chipmaker, including the ones it competes with. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.